Anzeige
Mehr »
Lynx Broker
Login
Dienstag, 22.10.2019 Börsentäglich über 12.000 News von 614 internationalen Medien
Folgen Sie der Spur! Kein Unternehmen hat bessere Karten! Und jetzt auch noch das…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0M95J ISIN: GB00B2B0DG97 Ticker-Symbol: RDEB 
Tradegate
21.10.19
19:01 Uhr
20,650 Euro
+0,260
+1,28 %
1-Jahres-Chart
RELX PLC Chart 1 Jahr
5-Tage-Chart
RELX PLC 5-Tage-Chart
RealtimeGeldBriefZeit
20,340
20,350
11:11
20,330
20,700
11:12
11.10.2019 | 18:55
(385 Leser)
(2 Bewertungen)

Leading oncology decision support tool to unveil new branding at Oncology Clinical Pathways Congress

BOSTON, Oct. 11, 2019 /PRNewswire/ -- Elsevier, a global information analytics business specializing in science and health, today introduced ClinicalPath as the new brand name for Via Oncology, the cancer care management and clinical decision support tool that won "Best Computerized Decision Support Solution" in the 2019 MedTech Breakthrough Awards. ClinicalPath will be featured at booth 103 at the Oncology Clinical Pathways Congress in Boston, Massachusetts, October 11-13, 2019.

Elsevier Logo

The rebrand of Via Oncology to ClinicalPath reflects Elsevier's commitment to providing oncology care teams with a clearer path to clinical decision making, by combining advanced technology with evidence-based content. ClinicalPath will continue to deliver guidance to oncologists based on the latest published evidence and best practices of physicians, helping to standardize care; connect patients to clinical trials; prompt orders for appropriate biomarker and genetic tests; enable actionable insight into care patterns; and ultimately improve patient outcomes through personalized treatment pathways. ClinicalPath covers more than 97 percent of the most common cancer cases in medical and radiation oncology and is delivered at the point-of-care through integration with leading electronic health record (EHR) technologies.

"The new ClinicalPath brand name reflects Elsevier's expanded focus on providing innovative, evidence-based guidance to help health professionals standardize care and improve outcomes," said Alison Powell, Senior Vice President, Global Marketing, Elsevier. "Together with oncology care teams across the globe, we will continue to reduce unwarranted care variability and support consistent, high-quality care for patients."

Across medical and radiation oncology, ClinicalPath consistently exceeds an 80 percent on-pathway rate, with oncologists opting to pursue treatments within the ClinicalPath recommended care guidelines. ClinicalPath has also been shown to increase the rate of patient accrual to clinical trials by up to four times the national average at practices focused on clinical research.

Visitors to Elsevier's booth at the Oncology Clinical Pathways Congress will be able to speak to experts to discuss how ClinicalPath can best support oncology care teams. Learn more at Elsevier.com/clinicalpath.

About Elsevier

Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we're committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com

Media contact

Christopher Capot
Elsevier
+1-917-704-5174
c.capot@elsevier.com

Logo: https://mma.prnewswire.com/media/754760/Elsevier_Logo.jpg


© 2019 PR Newswire